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Abstract
Introduction—Metabolite, lipid, and lipoprotein lipid profiling can provide novel insights into 
mechanisms underlying incident dementia and Alzheimer’s disease.
Methods—We studied eight prospective cohorts with 22,623 participants profiled by nuclear 
magnetic resonance or mass spectrometry metabolomics. Four cohorts were used for discovery 
with replication undertaken in the other four to avoid false positives. For metabolites that survived 
replication, combined association results are presented.
Results—Over 246,698 person-years, 995 and 745 cases of incident dementia and Alzheimer’s 
disease were detected, respectively. Three branched-chain amino acids (isoleucine, leucine, and 
valine), creatinine and two very low density lipoprotein (VLDL)-specific lipoprotein lipid 
subclasses were associated with lower dementia risk. One high density lipoprotein (HDL; the 
concentration of cholesterol esters relative to total lipids in large HDL) and one VLDL (total 
cholesterol to total lipids ratio in very large VLDL) lipoprotein lipid subclass was associated with 
increased dementia risk. Branched-chain amino acids were also associated with decreased 
Alzheimer’s disease risk and the concentration of cholesterol esters relative to total lipids in large 
HDL with increased Alzheimer’s disease risk.
Discussion—Further studies can clarify whether these molecules play a causal role in dementia 
pathogenesis or are merely markers of early pathology.
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1. Introduction
Dementia, including Alzheimer’s disease (AD), is a major public health problem with 
devastating physical, financial, and social consequences for patients, their caregivers, 
families, and society. Worldwide the cost of AD care in 2010 was $604 billion or 1% of the 
global gross domestic product [1]. However, despite over two decades of research on animal 
models and clinical trials, we still have no effective prevention or disease-modifying therapy 
for late-onset clinical dementia and AD. Dementia is increasingly recognized as a 
heterogeneous syndrome that would be best addressed with a multipronged approach to 
prevention and treatment, analogous to the multipronged and individually tailored use of 
statins, antihypertensives, antiplatelet agents, and vasodilators in persons with coronary 
artery disease. Identifying novel biology could suggest new circulating biomarkers for risk 
prediction and drug targets. Agnostic approaches such as genome wide genetic analyses 
have identified new biological pathways and molecules mediating microglial inflammation 
(TREM2) and endocytosis (BIN1, PICALM) as having a previously unsuspected key role in 
AD pathophysiology [2,3].
Blood metabolomics is an attractive tool for agnostic exploration of disease pathways for 
several reasons. Metabolites are small molecules that reflect the interplay of genetic and 
environmental factors, readily cross the blood-brain barrier and their levels are modifiable 
through dietary or pharmacological interventions. This recognition has spurred interest in 
using metabolomics as a tool to understand AD. For example, longitudinal studies in mouse 
models of AD have implicated perturbed polyamine metabolism, disturbances in essential 
amino acids, branched-chain amino acids (BCAA), and in the neurotransmitter serotonin 
along with imbalances in phospholipid and acylcarnitine homeostasis in both the brain and 
the blood [4]. Human studies in cerebrospinal fluid and plasma have to date only compared 
AD cases to controls in cross-sectional settings or attempted to identify markers predicting 
conversion from mild cognitive impairment (MCI) to clinical dementia [5–9]. However, in 
persons with MCI or dementia, it is not possible to determine if the observed metabolite 
changes are causal or secondary to disease-related processes. There has only been one prior 
study of preclinical AD that failed to detect any consistently reproducible signal [10].
We conducted a prospective study relating blood metabolites, lipid, and lipoprotein lipids 
quantified by nuclear magnetic resonance (NMR) or mass spectrometry (MS) metabolomics 
to risk of incident dementia and AD in eight longitudinal studies with a total of 22,623 
participants free of dementia at baseline: the FINRISK 1997 study, the Dietary, Lifestyle and 
Genetic determinants of Obesity and Metabolic Syndrome (DILGOM) study, the Whitehall 
II Study, the Estonian biobank study (EGCUT), the Health 2000, the Framingham Heart 
Study (FHS), the Rotterdam study (RS), and the Erasmus Ruchen Family (ERF) study. The 
first four cohorts were used in discovery analyses, and the remaining four were used for 
replication. For metabolites taken to replication, we present overall association results 
combined across all eight samples by meta-analysis.
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2. Methods
2.1. Cohorts
Eight prospective cohort studies were examined. Discovery cohorts were The National 
FINRISK Study 1997 (FINRISK 1997), DILGOM, Whitehall II, and the Estonian biobank 
study (EGCUT). Replication cohorts were the RS, ERF study, Health 2000 study, and the 
FHS. More detailed descriptions of each study are provided in the Supplementary Material 
(Supplements–Methods–Surveys).
Altogether, 22,623 participants were included in this study. The sample size and baseline 
characteristics of each study are presented in Supplementary Tables 1 and 2. All participants 
who at baseline examination had a history of doctor-diagnosed prevalent dementia, including 
AD, stroke, or other neurological disease affecting cognitive function, were excluded. No 
cognitive performance screening was conducted at baseline. Patients under 40 years of age 
were also excluded from all studies except ERF. All metabolite measurements were made 
from stored samples drawn at baseline of each cohort and no time-dependent covariates were 
used.
Dementia identification in FINRISK 1997, DILGOM, and Health 2000 cohorts was 
performed in the same manner, using country-wide, electronic health care registers: Causes 
of death Register, Hospital Discharge Register, and National Social Insurance Institution’s 
Drug Reimbursement Register. In the EGCUT study cohort, participants were linked to the 
Estonian Health Insurance database containing detailed information on all contacts with 
health care services and prescriptions, and Estonian Causes of Death Registry, whereas 
prevalent disease information was additionally retrieved from recruitment questionnaires. In 
the Whitehall II study, participants were linked to electronic health records for dementia 
ascertainment using three databases: the national hospital episode statistics database, the 
Mental Health Services Data Set, and the mortality register. In the ERF survey, we used 
register data from general practitioner’s databases (9 to 14 years after baseline visit). RS 
participants were screened for dementia at baseline and at follow-up examinations using a 
three-step protocol. Screen-positive participants subsequently underwent a more detailed 
examination and informant interview with the Cambridge Examination for Mental Disorders 
in the Elderly [11]. In addition, the total cohort was continuously monitored for dementia 
through computerized linkage of the study database with digitized medical records from 
general practitioners [11]. In the FHS, we screened participants at each examination, and 
between visits, for possible cognitive decline through a number of mechanisms, including an 
administration of the Folstein Mini-Mental Status Examination [12], participant and 
physician referrals, annual health status updates and review of medical records, and persons 
“flagged” as having possible cognitive decline underwent a more detailed 
neuropsychological and neurological evaluation. All cases were reviewed by a panel 
comprising at least one behavioral neurologist and one neuropsychologist. Details of end 
point detection are presented in the Supplementary Material (Supplements–Methods–
Surveys). The cohort-specific dementia and AD detection methods are described in 
Supplementary Table 3.
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2.2. Metabolomics analyses
A serum NMR metabolomics platform (Nightingale Health Ltd, Helsinki, Finland) was used 
to quantify 228 circulating metabolites, lipid or lipoprotein lipid measures in seven of the 
eight cohorts [13]. All tested metabolites are listed in Supplementary Table 4. This high-
throughput metabolomics platform provides simultaneous quantification of routine lipids, 
lipid concentrations of 14 lipoprotein subclasses, and major subfractions, and further 
abundant fatty acids, amino acids, ketone bodies, and gluconeogenesis-related metabolites in 
absolute concentration units. The measured variables include 148 primary measures 
quantified in absolute concentrations as well as selected ratios, primarily related to fatty 
acids and lipoprotein composition. The NMR platform has been applied extensively in 
epidemiological studies [14,15], and details of the experimentation have been described 
elsewhere [13,16]. NMR analysis was used in all cohorts except FHS. In the FHS cohort, 
liquid chromatographytandem mass spectrometry (LC-MS) has been used. LC-MS data 
were acquired using either an AB SCIEX 4000 QTRAP triple quadrupole mass spectrometer 
(positively charged polar compounds and lipids) or an AB SCIEX 5500 QTRAP triple 
quadrupole mass spectrometer (negatively charged polar compounds). Detailed protocols for 
the quantification of metabolites in the FHS have been previously published [17,18] and are 
described in Supplementary Material (Supplement–Methods–Metabolite analysis). A subset 
of 2638 serumsamples from the FINRISK 1997 study were additionally profiled with LC-
MS using the AbsoluteIDQ p180 Kit assay from Biocrates (Innsbruck, Austria). The 
correlations between circulating BCAA determined by NMR and LC-MS among the same 
individuals were fairly good as shown in Supplementary Fig. 1. The value of r2 was 0.61 
and 0.45 for valine and leucine, respectively.
2.3. Statistical analysis
In the discovery stage, we analyzed the associations of all metabolites, lipid, and lipoprotein 
lipid measures quantified by NMR metabolomics (n = 228) with incident dementia and AD. 
Two models were used: model 1 with age, sex, education grade, and number of 
apolipoprotein E (APOE) ε4 alleles as covariates and model 2 which additionally adjusted 
for systolic blood pressure, hypertension treatment, prevalent diabetes, current smoking, and 
any prevalent cardiovascular disease (atrial fibrillation, coronary heart disease, heart failure, 
stroke, or peripheral artery disease). Because some of the NMR metabolites are highly 
correlated, we performed a principal component analysis to estimate the number of 
independent tests and corrected the P-values for multiple testing accordingly. The principal 
component analysis was conducted in the FINRISK 1997 cohort and 95% of the variation of 
NMR metabolites, lipids, and lipoprotein lipids was explained by 25 principal components, 
giving the corresponding P-value of .002 (0.05/25) as statistically significant (type I error 
correction). We used Cox proportional hazards regression model to test the metabolite 
associations. Time from the baseline examination to incident dementia, AD, death, or the 
end of the follow-up was used as the timescale, and age was used as a covariate in all 
models. Hazard ratios (HRs) and their 95% confidence intervals are presented per 1-SD of 
the rank inverse normal transformed concentration; 1-SD change in units is presented in 
Supplementary Table 4. Proportional hazard assumption was tested in two discovery cohorts 
(FINRISK 1997, DILGOM), and violations were observed for 14 metabolites (marked with 
asterisk in Supplementary Table 6). None of these metabolites or lipoprotein lipids were 
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significant in the discovery analysis. All metabolites with P-value less than .002 in discovery 
meta-analyses were taken forward for testing in the replication cohorts. Because FHS did not 
use the NMR metabolomics platform, there were only a limited number of metabolites that 
could be replicated in the FHS cohort: valine, leucine, isoleucine, and creatinine. To examine 
the possible effect of selective mortality on our findings, we also conducted a sensitivity 
analysis using Fine-Gray subdistribution hazard modeling for the 10 discovered metabolites 
[19]. Death from any other cause than dementia was used as a competing risk in these 
models. The statistical analyses were carried out with R, version 3.2.3 or 3.3.1 using 
“survival,” “cmprsk,” and “meta” packages [20–22].
3. Results
The study included 22,623 subjects with 246,698 person-years of follow-up. In discovery 
cohorts, we observed altogether 329, 181, and 1435 cases of incident dementia, AD, and 
deaths from any cause, respectively. The EGCUT cohort did not record AD cases separately. 
The median follow-up times were 10.0, 7.9, 17.9, and 7.5 years (0.0, 0.1, 0.7, and 1.2 
interquartile range) in FINRISK 1997, DILGOM, Whitehall II, and EGCUT cohorts, 
respectively (Supplementary Table 1).
In replication cohorts, we observed altogether 666, 466, and 1405 cases of incident 
dementia, AD, and deaths from any cause, respectively (Supplementary Table 2). The 
baseline characteristics for all cohorts are presented in Supplementary Tables 1 and 2. The 
classical risk factors for dementia, used as covariates in our models, produced the expected 
results (Supplementary Table 5). Covariates are described in Supplementary Material 
(Supplement–Methods–Covariates). As a positive control, it is worth noting that the number 
of APOE ε4 alleles was strongly associated with the risk of incident dementia (HR = 2.51, 
95% confidence interval 2.00–3.16, P < .001, Supplementary Table 5)
3.1. Discovery and replication findings
In the discovery analyses (n = 15,161/329 study subjects/ cases of incident dementia), 
altogether 10metabolites or lipoprotein lipids were associated with incident dementia (P < .
002) (Table 1) and none with incident AD. All the results of discovery analyses are 
presented in the Supplementary Tables 6–9, for both models and both outcomes, dementia, 
and AD. The 10 metabolites and lipoprotein lipids were tested further in four replication 
cohorts (Health 2000, RS, ERF, and FHS), and these results are shown in Table 2 (dementia, 
model 2) and Supplementary Tables 10–12 (dementia model 1 and AD models 1–2). None 
of the statistically significant metabolite associations were driven by a single cohort and the 
results appeared to be consistent in all discovery and replication cohorts (Supplementary 
Figs. 2–3).
3.2. Meta-analysis of all cohorts
The results of the discovery and replication cohorts were combined in meta-analysis of all 
cohorts (n = 22,623/995 study subjects/cases of incident dementia). All three BCAAs 
(isoleucine, leucine, and valine) were inversely associated with incident dementia (model 2), 
(Fig. 1, Supplementary Tables 13 and 14). Also creatinine, total cholesterol in small VLDL 
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(S-VLDL-C), and triglycerides to total lipids ratio in very large VLDL were inversely 
associated with incident dementia (Fig. 1, Supplementary Tables 13 and 14). The 
concentration of cholesterol esters relative to total lipids in large HDL (L-HDL-CE-%) and 
total cholesterol to total lipids ratio in very large VLDL were directly associated with 
incident dementia (Fig. 1) (Supplementary Tables 13 and 14). The HRs for AD were broadly 
similar but smaller numbers of incident AD cases compared to incident dementia diluted the 
statistical significance of the results (Fig. 1, Supplementary Tables 15 and 16). The 
correlations between the metabolites associated with incident dementia are presented in 
Supplementary Table 17. Of note are the moderately strong correlations between the BCAAs 
and S-VLDL-C (r = 0.67–0.55).
3.3. Sensitivity analyses
We carried out two sensitivity analyses. First, to examine the influence of body mass index 
(BMI) and cholesterol-lowering medication on incident dementia and AD risk. Second, to 
examine the possible effects of selective mortality, we conducted Fine-Gray subdistribution 
hazard analysis for the 10 discovered metabolites. These analyses are briefly described in the 
next two paragraphs.
The associations of BCAAs, L-HDL-CE-%, and S-VLDL-C with incident dementia 
remained similar after adjusting for BMI and cholesterol-lowering medication 
(Supplementary Table 18). However none of the discovered metabolites were associated 
with incident AD after the analyses were adjusted for BMI and cholesterol-lowering 
medication (Supplementary Tables 18 and 19).
Next, we hypothesized that the associations of metabolites with incident dementia or AD 
might be confounded by a competing risk of death because the elevated levels of, for 
example, BCAA have been associated with metabolic syndrome, diabetes, and 
cardiovascular events. In Fine-Gray subdistribution hazard analysis, creatinine and BCAAs 
remained significantly associated with lower, and L-HDLCE-% with higher, dementia risk 
(Supplementary Table 20). S-VLVD-C was not associated with incident dementia in Fine-
Gray analysis (Supplementary Table 20). Other HDL- or VLDL lipoprotein subclasses were 
not associated with dementia risk in Fine-Gray analysis. We did not observe any statistically 
significant associations between metabolites and incident AD in Fine-Gray analysis. This is 
not surprising because all Fine-Gray results were adjusted for model 2 and BMI.
In a meta-analysis of FINRISK 1997, DILGOM, and Health 2000 results, we observed no 
interactions between metabolites, lipids, or lipoprotein lipids, and APOE ε4 genotype or sex 
on the association (P < .002) with incident dementia or AD.
4. Discussion
Our study identified 10 metabolites or lipoprotein lipids associated with the risk for 
clinically incident dementia across four discovery cohorts. Lower levels of the BCAA such 
as valine were associated with an increased risk of both all dementia and of AD in this 
discovery cohort and in a combined meta-analysis with a replication sample. In addition, we 
observed inverse associations of creatinine, total cholesterol in S-VLDL-C, and triglycerides 
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to total lipids ratio in very large VLDL with incident dementia, but not with AD in the 
discovery cohort alone. In meta-analysis, the concentration of L-HDL-CE-% was associated 
with an increased risk of AD.
We tested 228 metabolic measures quantified by serum NMR metabolomics in the discovery 
sample. We chose a conservative strategy of initial discovery followed by independent 
replication of a hard clinical end point, to minimize the risk of reporting false-positive 
associations, a pitfall that has impacted earlier reports. This may have however reduced our 
ability to identify some true associations, for example, with docosahexaenoic acid which, in 
addition to earlier literature [23,24], was recently discovered to associate with higher general 
cognitive ability in a study based partly on the same cohorts as the present study (Sven J. van 
der Lee, personal communication, article submitted).
To our knowledge, the inverse association of BCAAs with clinical dementia has not been 
reported previously. In line with our results, Toledo et al. observed higher valine level to be 
associated with slower cognitive decline and lesser cerebral atrophy change in the 
“Alzheimer’s Disease Neuroimaging Initiative” cohort [25].
Although there are biologically plausible explanations for such an association for what we 
describe, subsequently we wished to explore whether these findings could represent reverse 
causality or selective survival. Valine, leucine, and isoleucine are essential BCAAs, and 
circulating levels are largely determined by dietary intake. Thus, reduced levels of these 
essential amino acids might indicate subclinical nutritional deficiencies in persons with 
preclinical dementia and MCI [26]. Indeed, in later life, weight loss is known to be 
associated with a higher risk of dementia, and it has been associated with declining BCAA 
levels [27,28]. However, plasma albumin, which is used as a marker of nutrition, was not 
related to dementia risk and BCAA’s HRs for incident dementia remained similar after 
adjusting for BMI. BCAAs are also associated with muscle mass [29], which is consistent 
with our observation of an inverse association of creatinine and dementia risk. Hence, it is 
possible that these metabolites are early markers of MCI, reduced physical activity, and 
muscle mass.
Competing risk of death in persons with elevated BCAA levels is not likely to explain the 
observed inverse associations with incident dementia because BCAAs remained associated 
with incident dementia in Fine-Gray subdistribution model. In a recent study, Pedersen et al 
demonstrated that gut microbiota are an independent source of BCAAs [30], but these have 
not been examined in relation to dementia risk although changes in gut microbiota have been 
associated with other neuropsychiatric diseases [31].
Lower cerebrospinal fluid valine has been recorded in persons with AD dementia compared 
to controls [32], although some studies have shown low valine in MCI and higher values in 
AD [33]. In a small cross-sectional study, no differences were seen in BCAA blood levels 
among healthy controls, patients with MCI, and those with AD [34], but an independent 
cross-sectional study identified valine, among other metabolites, as an indicator for disease 
progression from MCI to AD [33]. It is hypothesized that circulating BCAAs could have an 
important role in glutamate synthesis and could also buffer toxic levels of glutamate [35]. 
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Glutamate is the most abundant excitatory neurotransmitter and binds to cell surface 
receptors like α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and N-
methyl-D-aspartate receptors [36]. Because N-methyl-D-aspartate-receptor hypofunction 
seems to be related to calcium ion dysregulation and impaired synaptic plasticity [37], it is 
possible that the association of reduced levels of BCAA to dementia and AD is mediated 
through this pathway [33]. Higher valine has also been associated with increased apoptosis 
in maple syrup urine disease, and lower valine in preclinical AD could be a compensatory 
phenomenon in response to activation of apoptotic pathways [38]. Nevertheless, it should be 
noted that once the models were adjusted for BMI and cholesterol-lowering medication, the 
associations between BCAAs and incident AD were no longer statistically significant. The 
robust association of these metabolites with all dementia and vanishing association with AD 
may reflect the smaller numbers of AD cases or be due to a stronger association with 
vascular dementia.
A VLDL-receptor polymorphism has been reported to associate with dementia risk, 
especially with mixed and vascular dementia [39]. We detected total VLDL cholesterol to be 
inversely associated with dementia risk as did Lara et al. [40] The association between 
VLDL cholesterol and cardiovascular events [14,41] is one possible explanation for our 
observation. In addition, we observed one VLDL lipoprotein subclass to decrease 
(triglycerides to total lipids ratio in very large VLDL) and one to increase (total cholesterol 
to total lipids ratio in very large VLDL) the dementia risk. To the best of our knowledge, no 
association between large HDL lipoprotein and dementia risk has been published previously. 
Cholesterol-lowering medication affects lipoprotein levels, and these associations, except L-
HDL-CE-% and S-VLDL-C, with incident dementia were attenuated after adjusting for BMI 
and cholesterol-lowering medication. Association of S-VLDL-C with incident dementia can 
be largely explained by increased selective mortality. We believe that the associations 
between HDL lipoprotein and VLDL lipoprotein subclasses and dementia risk need more 
research because our findings and the previous studies are inconclusive.
We did not observe any robust associations of cholesterols, triglycerides, phospholipids, 
apolipoproteins, fatty acids, glycolysis-related metabolites, ketone bodies, fluid balance 
metabolites, or inflammation markers with incident dementia or AD. In previous studies, 
several specific phospholipids have been shown to associate with the risk of conversion of 
MCI to AD [6,9], but the metabolomics platform used here does not share the same 
phospholipids reported on in those earlier studies.
Our results also differ from prior studies which suggested an association of sphingomyelin 
and docosahexaenoic acid with dementia and AD [6,23,24,42]; these differences could be 
due to chance or differences in dietary patterns or genetic risk between the cohorts studied 
here and in early reports. Docosahexaenoic acid and eicosapentaenoic acid dietary 
supplements have been associated with better cognitive function [43,44], and lower odds of 
dementia and AD (personal communication, Sven J. van der Lee) in some studies but two 
large meta-analyses did not show an association, suggesting that this area deserves further 
scrutiny including possible gene-environment interactions [45]. Our conservative statistical 
strategy and lower sensitivity to detect some associations may partly explain these 
differences between our study and previous studies as described above.
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We did not observe any effect modification of the metabolites or lipoprotein lipids by APOE 
genotype or sex in their effect on dementia or AD risk. We did not observe any robust 
associations with absolute concentrations of lipoproteins and incident dementia or AD. This 
is in line with previous genetic studies where no causal effect of circulating levels of HDL 
cholesterol, serum total cholesterol, LDL cholesterol, or triglycerides on incident AD was 
seen, despite the genetic associations with the APOE and ABCA7 loci [46,47]. Age, 
education level, APOE genotype, and prevalent diabetes were the only covariates associated 
with incident dementia in this study. We did not observe statistically significant association 
between incident dementia and smoking, systolic blood pressure, heart failure, or atrial 
fibrillation. This is not surprising because the analyses were not designed to investigate these 
associations, and survival bias likely affects these results.
The strengths of our study include the large samples and prospective population-based 
design with separate discovery and replication cohorts. Furthermore, all NMR metabolomics 
measurements were carried out in the same laboratory following the same protocol, and only 
one cohort used a different methodology. Limitations of the study include some differences 
between cohorts in the methods used to identify cases of incident dementia. Most cohorts 
relied on electronic health registers, which leads to virtually complete follow-up and high 
specificity but may have limited sensitivity [48]. The lower sensitivity potentially reduces 
the power to detect statistically significant associations but should not result in spurious 
associations. Moreover, the findings were replicated in prospective cohorts such as the RS 
and FHS that used more sensitive, surveillance-based outcome ascertainment. Some cohorts 
were unable to distinguish AD from other dementias, which led to a reduced statistical 
power for the AD analysis. Ethnic homogeneity of our largely Caucasian sample limits the 
generalizability of these results to other populations with different ethnic backgrounds. Also, 
the FHS used an MS platform, and therefore, only a limited set of metabolites were in 
common between the FHS and other cohorts. The main association we report here, of 
BCAA, was however directionally consistent in FHS and the other cohorts and the 
correlations between the BCAAs measured using MS and NMR were reasonably strong.
Several next steps can be considered to clarify our findings further. The earlier studies that 
have reported an association between BCAA and metabolic syndrome and diabetes risk, 
should be examined for availability of cognitive end points and possible confirmation of the 
present findings. Furthermore, a Mendelian randomization study on BCAA and other 
metabolites and incident dementia or AD should help with causal inferences. A Mendelian 
randomization study on BCAAs and risk of type 2 diabetes has been published suggesting 
that suitable single-nucleotide polymorphisms exist [49], although this work has been 
recently criticized for the possibility of misinterpretation due to pleiotropism [50]. If further 
evidence supporting causality is obtained, a clinical trial supplementing BCAA in diet could 
be considered but such a trial should be carefully designed and monitored also for diabetes 
and other metabolic outcomes. A wider angle is the rapidly increasing availability of 
metabolomics profiling. Researchers should consider establishing an international 
metabolomics consortium aiming at harmonizing measures and analysis protocols across 
metabolomics platforms and cohorts, so that data already collected can be meta-analyzed. 
This would also encourage metabolomics studies in other geographical areas and other 
ethnic groups, which are clearly needed. Another line of research that is worth pursuing in 
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parallel to confirming the discovery findings is the prediction of dementia or AD risk. Even 
if not causal, these biomarkers may improve the prediction of incident dementia or AD over 
and above the currently used risk scores. This in turn could enable earlier starting and better 
targeting of medical and other treatments, which has the potential to slow down the cognitive 
decline.
In conclusion, our large prospective study identified lower BCAA levels to be associated 
with an increased risk of incident dementia, independent of other conventional risk factors. 
Moreover, creatinine, one HDL, and three VLDL lipoprotein subclasses were also associated 
with dementia risk, but these associations disappeared when adjusted for BMI and 
cholesterol-lowering medication. Further studies are needed to explore whether these 
metabolites play a role in the etiology and pathogenesis of dementia, or reflect reverse 
causation, that is, they are biomarkers for systemic or lifestyle changes in the preclinical 
stages of dementia. In either case, if corroborated in other studies, these biomarkers may 
help in early identification of persons at risk of dementia and initiation of preventive and 
treatment measures.
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Refer to Web version on PubMed Central for supplementary material.
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RESEARCH IN CONTEXT
1. Systematic review: Blood metabolites are small molecules that reflect the 
interplay between genetic and environmental factors, readily cross the blood-
brain barrier, and have the potential to play a role in the development of 
dementia. Well-powered prospective studies on metabolome and incident 
dementia or Alzheimer’s disease are limited at the moment.
2. Interpretation: We carried out a large prospective study on metabolite, lipid, 
and lipoprotein lipid associations with incident dementia and Alzheimer’s 
disease in eight cohorts. Branched-chain amino acids isoleucine, leucine, and 
valine and cholesterol ester ratio in large HDL had robust associations with 
the risk of dementia and Alzheimer’s disease. Selective mortality did not 
explain these associations.
3. Future directions: Future mechanistic studies should examine whether the 
identified metabolites or lipoprotein lipids play etiologic roles in the 
development of dementia or whether they are early biomarkers of mild 
cognitive decline and developing physical frailty.
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Fig. 1. 
A forest plot describing the meta-analysis results of all eight cohorts combined (n = 
22,623/995, participants/incident dementia cases). Results are adjusted for model 2. Model 2 
includes age, sex, education grade, number of APOE ε4 alleles, systolic blood pressure, 
hypertension treatment, prevalent diabetes, current smoking, and any prevalent 
cardiovascular disease (atrial fibrillation, coronary heart disease, heart failure, stroke, or 
peripheral artery disease) as covariates. HRs and 95% CIs are shown per one SD of rank 
inverse normal transformed metabolite concentration. Abbreviations: APOE, apolipoprotein 
E; CIs, confidence intervals; HRs, hazard ratios; SD, standard deviation; AD, Alzheimer’s 
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disease; CREA, creatinine; SFA-FA, Ratio of saturated fatty acids to total fatty acids; ILE, 
isoleucine; LEU, leucine; VAL, valine; L-HDL-CE-%, Cholesterol esters to total lipids ratio 
in large HDL; L-HDL-PL-%, phospholipids to total lipids ratio in large HDL; S-VLDL-C, 
Total cholesterol in small VLDL; XL-VLDL-C-%, Total cholesterol to total lipids ratio in 
very large VLDL; XL-VLDL-TG-%, Triglycerides to total lipids ratio in very large VLDL.
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Table 2
Replication results of the 10 preliminary significant metabolites associated with incident dementia in four 
separate cohorts
Metabolite, lipid, lipoprotein 
lipid
Health 2000, HR (95% CI) Rotterdam, HR (95% CI) ERF, HR (95% CI) FHS, HR (95% CI)
Creatinine 1.19 (0.87; 1.63) 0.94 (0.84; 1.06) 0.82 (0.57; 1.18) 0.97 (0.78; 1.2)
SFA-FA 1.08 (0.78; 1.49) 0.94 (0.84; 1.04) 1.15 (0.61; 2.2) NA
Isoleucine 0.87 (0.61; 1.25) 0.9 (0.8; 1.01) 0.66 (0.42; 1.03) 1.05 (0.84; 1.3)
Leucine 0.94 (0.69; 1.3) 0.84 (0.74; 0.94) 0.91 (0.6; 1.37) 0.94 (0.75; 1.19)
Valine 0.93 (0.68; 1.26) 0.86 (0.76; 0.96) 0.84 (0.55; 1.29) 0.96 (0.76; 1.19)
L-HDL-CE-% 0.99 (0.71; 1.38) 1.04 (0.94; 1.17) 1.08 (0.61; 1.91) NA
L-HDL-PL-% 1.09 (0.8; 1.49) 1.04 (0.94; 1.16) 1.25 (0.74; 2.11) NA
S-VLDL-C 0.89 (0.64; 1.23) 0.91 (0.82; 1.01) 1.08 (0.59; 1.97) NA
XL-VLDL-C-% 0.87 (0.65; 1.16) 1.07 (0.95; 1.19) 0.67 (0.3; 1.49) NA
XL-VLDL-TG-% 1.19 (0.87; 1.63) 0.94 (0.84; 1.06) 0.82 (0.57; 1.18) 0.97 (0.78; 1.2)
Abbreviations: ERF, Erasmus Ruchen Family; FHS, Framingham Heart Study; SFA-FA, Ratio of saturated fatty acids to total fatty acids; L-HDL-
CE-%, Cholesterol esters to total lipids ratio in large HDL; S-VLDL-C, Total cholesterol in small VLDL; XL-VLDL-C-%, Total cholesterol to total 
lipids ratio in very large VLDL; XL-VLDL-TG-%, Triglycerides to total lipids ratio in very large VLDL; APOE, apolipoprotein E.
NOTE. Hazard ratio (HR) and 95% confidence intervals (CI) are shown per one standard deviation (SD) of rank inverse normal transformed 
metabolite concentration. Adjusted for model 2*.
*
Model 2 includes age, sex, education grade, and number of APOE ε4 alleles plus systolic blood pressure, hypertension treatment, prevalent 
diabetes, current smoking, and any prevalent cardiovascular disease (atrial fibrillation, coronary heart disease, heart failure, stroke, or peripheral 
artery disease) as covariates.
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